September 22, 2025

Quick IPO snapshot (at a glance) Note: SME IPOs usually have larger lot sizes and different allotment rules; always confirm exact retail application limits with your broker or the RHP before bidding. (aptus-pharma.com) About Aptus Pharma Ltd Aptus Pharma Limited is a Gujarat-based pharmaceutical company that filed a Draft Red Herring Prospectus (DRHP) for a BSE SME listing. The company operates in the pharmaceutical manufacturing/supply space — contract manufacturing, formulations or similar pharma operations (see RHP/DRHP for the precise product mix and manufacturing footprint). The IPO being a 100% fresh-issue seeks to raise growth capital and expand the company’s operations. (HDFC Sky) (For detailed legal & operational disclosures — manufacturing units, manufacturing capacity, licences, and risk factors — refer to the company’s RHP/DRHP PDF.) (Sharekhan) Key management Key management details, board composition and promoter holding are published in the DRHP — the promoters retained a significant stake pre-IPO and post-IPO promoter holding remains high (typical for SME issues). For exact names, experience and promoter shareholding percentages refer to the official RHP. (Sharekhan) Major products / business lines Aptus Pharma’s product / service mix and major SKUs are listed in the prospectus — expect conventional pharma formulations/contract manufacturing offerings typical of small-to-mid Indian pharma firms. For the precise product list and client/customer concentrations, check the RHP. (Sharekhan) Financials (high-level) These numbers come from the company’s DRHP/RHP and analyst portals summarising the RHP — always cross-check figures directly in the prospectus before taking a decision. (Sharekhan) Competitors and market context Aptus Pharma competes with other regional/small-cap pharma manufacturers and contract manufacturers operating in formulations and related niches. Comparable listed peers include small-cap pharma firms on BSE/NSE and SME-listings that serve domestic generic markets or contract manufacturing. Competitive risks include pricing pressure, regulatory compliance, customer concentration and margin sensitivity to raw material costs. (For a precise peer list, search comparable BSE SME & small-cap pharma names operating in similar formulations/contract manufacturing segments.) (HDFC Sky) Pros (what looks good) Cons / Risks (what to watch) Conclusion — short take Aptus Pharma shows improving financials and is raising a modest amount via a BSE SME issue. The fundamentals (growth in revenue and profit) are encouraging on paper, but the SME nature, large minimum investment (lot size), promoter concentration, and limited liquidity are material risks. (IPO Watch)